Valneva SEINRLF 60 Days Payable is 54.02 as of Mar. 2026, which is 4% below its 10-year median of 56.04. GuruFocus rates INRLF with a GF Score™ of 60/100 and a GF Value™ of $2.84 (Fairly Valued). The stock has 6 warning signs investors should review. Among 703 Biotechnology companies, Valneva SE ranks worse than 62.59% on this metric.
Valneva SE's average Accounts Payable for the
three
months ended in Mar. 2026 was $17.9 Mil. Valneva SE's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $30.3 Mil.
Hence, Valneva SE's Days Payable for the
three
months ended in Mar. 2026 was 54.02.
The historical rank and industry rank for Valneva SE's Days Payable or its related term are showing as below:
INRLF'
s Days Payable Range Over the Past 10 Years
Min: 17.18 Med: 56.04 Max: 113.48
Current: 62.57
During the past 13 years, Valneva SE's highest Days Payable was 113.48. The lowest was 17.18. And the median was 56.04.
INRLF's Days Payable is ranked worse than 62.59% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs INRLF: 62.57
Valneva SE's Days Payable
declined
from Mar. 2025 (79.35) to Mar. 2026 (54.02).
It may suggest that Valneva SEaccelerated paying its suppliers.
Valneva SE Days Payable Related Terms
Valneva SE Days Payable Historical Data
* Premium members only.
The historical data trend for Valneva SE's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INRLF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Valneva SE's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Days Payable distribution charts can be found below:
* The bar in red indicates where Valneva SE's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Valneva SE's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (INRLF) has a Days Payable of 54.02 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valneva SE and its competitors. This is near median its historical median of 56.04. Over the past decade, Valneva SE's Days Payable has ranged from 17.18 to 113.48. According to the industry distribution chart, Valneva SE ranks #440 out of 703 companies in the Biotechnology industry, placing it in the top 62.6%.
Is Valneva SE's Days Payable too high?
Valneva SE's current Days Payable of 54.02 is near median its 10-year median of 56.04. Over the past 10 years, this metric has ranged from a low of 17.18 to a high of 113.48. The Biotechnology industry median Days Payable is 113.76. Valneva SE's value of 54.02 is 52.5% below this industry median. Based on the distribution chart, Valneva SE ranks #440 out of 703 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Valneva SE has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #440 out of 703 companies for Days Payable. This places Valneva SE in the lower half of its industry. The industry median Days Payable is 113.76. Valneva SE's value of 54.02 is 52.5% below this benchmark. Historically, Valneva SE's own Days Payable has ranged from 17.18 to 113.48 over the past decade. While the company's 10-year median is 56.04 vs. the industry median of 113.76, Valneva SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current Days Payable of 54.02 is 52.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Days Payable is 54.02, which is near median its own 10-year median of 56.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.84, compared to a current price of $2.62 — trading 7.7% below its estimated fair value. The current Days Payable is 54.02, which is near median its 10-year median of 56.04 and 52.5% below the Biotechnology industry median of 113.76. Valneva SE's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Valneva SE (INRLF), the current Days Payable is 54.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 7.7% below its estimated GF Value™ of $2.84.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for INRLF:
Days Payable: 54.02 (near median its 10-year median of 56.04)
GF Value™: $2.84 vs. price of $2.62 (7.7% below fair value)
Industry Position: 52.5% below the Biotechnology median (#440 of 703)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
60GF Score
Get the complete analysis for INRLF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
